Literature DB >> 11530143

Enzyme-replacement therapy for Anderson-Fabry disease.

G M Pastores1, R Thadhani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11530143     DOI： 10.1016/S0140-6736(01)05816-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?

Authors:  S R Ommen; R A Nishimura; W D Edwards
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

2.  Treatment of lysosomal storage disorders.

Authors:  Atul B Mehta; Susan Lewis; Christine Laverey
Journal:  BMJ       Date:  2003-08-30

3.  Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience.

Authors:  Joanna Ghali; Kathy Nicholls; Charles Denaro; David Sillence; Ian Chapman; Jack Goldblatt; Mark Thomas; Janice Fletcher
Journal:  JIMD Rep       Date:  2011-09-15

4.  Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

Authors:  Daniël Blom; Dave Speijer; Gabor E Linthorst; Wilma G Donker-Koopman; Anneke Strijland; Johannes M F G Aerts
Journal:  Am J Hum Genet       Date:  2002-12-06       Impact factor: 11.025

5.  Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.

Authors:  D Hajioff; Y Enever; R Quiney; J Zuckerman; K Mackermot; A Mehta
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 6.  Substrate reduction therapy in mouse models of the glycosphingolipidoses.

Authors:  Frances M Platt; Mylvaganam Jeyakumar; Ulrika Andersson; Tanya Heare; Raymond A Dwek; Terry D Butters
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

7.  A historical perspective of the glycosphingolipids and sphingolipidoses.

Authors:  Richard W E Watts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

Review 8.  Update on role of agalsidase alfa in management of Fabry disease.

Authors:  Uma Ramaswami
Journal:  Drug Des Devel Ther       Date:  2011-03-14       Impact factor: 4.162

9.  Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Authors:  Anouk C Vedder; Gabor E Linthorst; Gunnar Houge; Johannna E M Groener; Els E Ormel; Berto J Bouma; Johannes M F G Aerts; Asle Hirth; Carla E M Hollak
Journal:  PLoS One       Date:  2007-07-11       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.